RxDoctor Payments Data

Hallie Guenther

Psychiatric/Mental Health · Buffalo, NYNPI 1356815468

Payments from drug & device makers

$1,788in general payments, 2019–2025

Across 29 payments — averaging $61.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$527
  • AbbVie$498
  • Otsuka America Pharmaceutical, Inc.$242
  • Neurocrine Biosciences, Inc.$139
  • Vanda Pharmaceuticals Inc.$125
  • Teva Pharmaceuticals USA, Inc.$125
  • plus $132 from 2 others

What the payments were for

  • Food & beverage$1,74197%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,788 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$6,346
Medicare patients
31
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$102,260
Invega SustennaPaliperidone Palmitate13$46,568
Abilify MaintenaAripiprazole15$41,428
VraylarCariprazine Hcl13$21,281
Aripiprazole160$4,738
Duloxetine Hcl151$3,438
Quetiapine Fumarate ErQuetiapine Fumarate47$2,542
Quetiapine Fumarate128$2,448
Lurasidone Hcl15$1,865
Fluoxetine Hcl107$1,515
Olanzapine42$1,339
Buspirone Hcl116$1,314
Oxcarbazepine15$1,111
Clonazepam91$995
Risperidone64$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$139$102,26012 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$242$41,42815 claims
AbbVieVraylar$498$21,28113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →